Media coverage about Biogen (NASDAQ:BIIB) has been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biogen earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.8067925765178 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Profit From the Biogen Inc (BIIB) Stock Dip! (investorplace.com)
- RBC Capital Starts Coverage on Biogen Inc. (BIIB) Giving It An Initial Rating Of “Sector Perform” – First News 24 (firstnewspaper24.com)
- Biogen Inc. (BIIB) Now Covered by Analysts at Royal Bank Of Canada (americanbankingnews.com)
- Biogen Inc. (BIIB) 10.00% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Biogen Inc. (NASDAQ:BIIB) Shares Bought by Marshall Wace LLP (newstrendstoday.com)
A number of brokerages have recently commented on BIIB. Royal Bank of Canada began coverage on Biogen in a report on Thursday, September 14th. They issued a “sector perform” rating and a $319.00 price target on the stock. BMO Capital Markets boosted their price target on Biogen from $328.00 to $377.00 and gave the company a “market perform” rating in a report on Wednesday, September 13th. Mizuho restated a “neutral” rating and issued a $319.00 price target (up from $274.00) on shares of Biogen in a report on Wednesday, September 13th. Vetr upgraded Biogen from a “hold” rating to a “buy” rating and set a $346.83 price target on the stock in a report on Thursday, September 7th. Finally, ValuEngine lowered Biogen from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Thirteen equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $331.53.
Shares of Biogen (NASDAQ BIIB) traded down 0.08% during midday trading on Tuesday, hitting $317.93. The stock had a trading volume of 779,263 shares. The company has a market cap of $67.22 billion, a price-to-earnings ratio of 20.86 and a beta of 0.77. The stock’s 50-day moving average price is $300.47 and its 200 day moving average price is $278.47. Biogen has a 52 week low of $244.28 and a 52 week high of $330.00.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company had revenue of $3.08 billion during the quarter, compared to analyst estimates of $2.81 billion. During the same quarter last year, the business posted $5.21 EPS. Biogen’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, equities analysts forecast that Biogen will post $21.50 earnings per share for the current year.
In other news, EVP Susan H. Alexander sold 7,758 shares of the firm’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the completion of the sale, the executive vice president now owns 27,232 shares in the company, valued at approximately $7,761,120. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Susan H. Alexander sold 4,974 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the sale, the executive vice president now owns 22,258 shares of the company’s stock, valued at approximately $6,455,042.58. The disclosure for this sale can be found here. Company insiders own 0.32% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/09/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-biogen-biib-stock-price-2.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.